BridgeBio Pharma, Inc.
BBIOAPI behind this page
BBIO Q1 2026 request
Playground key active
/api/financials?ticker=BBIO&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 194,515 | 116,633 | +66.8% |
Show Product Lines breakouts |
|||
| Cost of license, services, and royalty revenue · Bayer | 10.3 | — | — |
| License And Service | 4,419 | 79,690 | -94.5% |
| License And Service · Alexion License Agreements | 1.3 | 1 | +30.0% |
| License And Service · Kyowa Kirin Co., Ltd | 2.2 | 2.7 | -18.5% |
| License And Service · Reportable Segment | 4,419 | 79,690 | -94.5% |
| Product | 180,596 | 36,739 | +391.6% |
| Product · Bayer | 1 | 0.6 | +66.7% |
| Product · Reportable Segment | 180,596 | 36,739 | +391.6% |
| Royalty | 9,500 | 204 | +4556.9% |
| Royalty · Reportable Segment | 9,500 | 204 | +4556.9% |
Show Business Segments breakouts |
|||
| Reportable Segment | 194,515 | 116,633 | +66.8% |
| Cost of Revenue | 9,939 | 2,639 | +276.6% |
Show Product Lines breakouts |
|||
| Cost of license, services, and royalty revenue | 2,207 | 605 | +264.8% |
| Cost of license, services, and royalty revenue · Reportable Segment | 2,207 | 605 | +264.8% |
| Product | 7,732 | 2,034 | +280.1% |
| Product · Reportable Segment | 7,732 | 2,034 | +280.1% |
Show Business Segments breakouts |
|||
| Reportable Segment | 9,939 | 2,639 | +276.6% |
| Research & Development | 126,636 | 111,431 | +13.6% |
Show Business Segments breakouts |
|||
| Reportable Segment | 126,636 | 111,431 | +13.6% |
| Reportable Segment · Acoramidis for the treatment of ATTR-CM and primary prevention in asymptomatic carriers of a pathogenic TTR variant | 31,391 | 24,392 | +28.7% |
| Reportable Segment · BBP-418 for LGMD2I/R9 | 15,608 | 14,209 | +9.8% |
| Reportable Segment · Encaleret for ADH1 | 20,428 | 15,459 | +32.1% |
| Reportable Segment · Infigratinib for achondroplasia and hypochondroplasia | 35,533 | 27,934 | +27.2% |
| Reportable Segment · Other development programs | 6,760 | 11,430 | -40.9% |
| Reportable Segment · Other research programs | 16,916 | 18,007 | -6.1% |
| Selling, General & Administrative | 163,896 | 106,365 | +54.1% |
Show Business Segments breakouts |
|||
| Reportable Segment | 163,896 | 106,365 | +54.1% |
| Total Costs & Expenses | 300,471 | 221,005 | +36.0% |
Show Business Segments breakouts |
|||
| Reportable Segment | 300,471 | 221,005 | +36.0% |
| Operating Income | -105,956 | -104,372 | -1.5% |
Show Business Segments breakouts |
|||
| Reportable Segment | -105,956 | -104,372 | -1.5% |
| Interest Income | 6,246 | 5,385 | +16.0% |
Show Business Segments breakouts |
|||
| Reportable Segment | 6,246 | 5,385 | +16.0% |
| Interest Expense | -12,942 | -18,121 | +28.6% |
Show Business Segments breakouts |
|||
| Reportable Segment | -12,942 | -18,121 | +28.6% |
| Noncash Interest Expense On Deferred Royalty Obligations | -39,873 | -24,020 | -66.0% |
Show Business Segments breakouts |
|||
| Reportable Segment | -39,873 | -24,020 | -66.0% |
| Reportable Segment · Related Party | -5,361 | — | — |
Show Related Party Transactions By Related Party breakouts |
|||
| Related Party | -5,361 | — | — |
| Income Loss From Equity Method Investments | -18,283 | -15,556 | -17.5% |
Show Business Segments breakouts |
|||
| Reportable Segment | -18,283 | -15,556 | -17.5% |
Show Schedule Of Equity Method Investment Equity Method Investee Name breakouts |
|||
| BridgeBio Oncology Therapeutics, Inc. | -11.7 | -8.7 | -34.5% |
| Gondola Bio, LLC | -6.4 | -6.8 | +5.9% |
| Other Non-Operating Income (Expense) | 4,253 | 8,231 | -48.3% |
Show Business Segments breakouts |
|||
| Reportable Segment | 4,253 | 8,231 | -48.3% |
| Non-Operating Income (Expense) | -60,599 | -65,236 | +7.1% |
Show Business Segments breakouts |
|||
| Reportable Segment | -60,599 | -65,236 | +7.1% |
| Net Income | -166,555 | -169,608 | +1.8% |
Show Business Segments breakouts |
|||
| Reportable Segment | -166,555 | -169,608 | +1.8% |
| Net Income Loss Attributable To Noncontrolling Interest | 2,512 | 2,186 | +14.9% |
Show Business Segments breakouts |
|||
| Reportable Segment | 2,512 | 2,186 | +14.9% |
| Net Income Loss Available To Common Stockholders Basic | -164,043 | -167,422 | +2.0% |
Show Business Segments breakouts |
|||
| Reportable Segment | -164,043 | -167,422 | +2.0% |
| EPS (Basic) | -0.84 | -0.88 | +4.5% |
| EPS (Diluted) | -0.84 | -0.88 | +4.5% |
| Wtd Avg Shares (Basic) | 194,789,897 | 190,145,253 | +2.4% |
| Wtd Avg Shares (Diluted) | 194,789,897 | 190,145,253 | +2.4% |
| Operating Expenses (Q) | — | — | — |
Show Counterparty Name breakouts |
|||
| Gondola Bio, LLC · Transition Service Agreement And Sublease Agreement | 1.9 | 0.8 | +137.5% |
| Comprehensive Income | -164,063 | -167,430 | +2.0% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 879,891 | 540,599 | +62.8% |
| Available For Sale Securities Debt Securities Current | 60,295 | — | — |
| Accounts Receivable | 205,226 | 115,265 | +78.0% |
Show Counterparty Name breakouts |
|||
| Alexion License Agreements | 0.3 | 0.4 | -25.0% |
| Bayer | 10.2 | 75.8 | -86.5% |
| Inventory | 32,980 | 3,954 | +734.1% |
| Prepaid Expenses & Other Current Assets | 62,914 | 35,355 | +77.9% |
Show Counterparty Name breakouts |
|||
| BridgeBio Oncology Therapeutics, Inc. · Transition Service Aggrement | 0.8 | 0.5 | +60.0% |
| Gondola Bio, LLC · Transition Service Agreement And Sublease Agreement | 4.6 | 2.6 | +76.9% |
| Total Current Assets | 1,241,306 | 695,173 | +78.6% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 4,941 | 6,698 | -26.2% |
| Operating Lease Right-of-Use Assets | 17,226 | 7,166 | +140.4% |
| Other Non-Current Assets | 18,620 | 16,608 | +12.1% |
| Total Assets | 1,370,981 | 881,638 | +55.5% |
| Intangible Assets | 27,359 | 27,802 | -1.6% |
| Other Assets | |||
| Equity Method Investments | 61,529 | 34.7 | +177217.0% |
Show Schedule Of Equity Method Investment Equity Method Investee Name breakouts |
|||
| BridgeBio Oncology Therapeutics, Inc. | 60.8 | 93.5 | -35.0% |
| Intangible Assets Net Excluding Goodwill | 27,359 | 27,802 | -1.6% |
| Current Liabilities | |||
| Accounts Payable | 29,058 | 27,525 | +5.6% |
| Employee Related Liabilities Current | 39,338 | 33,447 | +17.6% |
| Accrued Research And Development Liabilities Current | 54,430 | 33,630 | +61.8% |
| Operating Lease Liability Current | 4,439 | 5,209 | -14.8% |
| Deferred Revenue (Current) | 6,115 | — | — |
Show Product Lines breakouts |
|||
| Research and Development Services · Bayer | 0.8 | — | — |
Show Counterparty Name breakouts |
|||
| Alexion License Agreements | 1 | — | — |
| Kyowa Kirin Co., Ltd | 4.3 | — | — |
| Current Portion of Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| 2027 Notes, net | 547,483 | — | — |
| Other Liabilities Current | 135,509 | 40,674 | +233.2% |
Show Counterparty Name breakouts |
|||
| Gondola Bio, LLC · Transition Service Aggrement | 1.5 | — | — |
Show Related Party Transactions By Related Party breakouts |
|||
| Related Party | 3,622 | 1.9 | +190531.6% |
| Total Current Liabilities | 816,372 | 152,105 | +436.7% |
| Non-Current Liabilities | |||
| Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| 2029 Notes, net | 741,402 | — | — |
| 2031 Notes, net | 565,045 | — | — |
| 2033 Notes, net | 619,631 | — | — |
| Operating Lease Liabilities | 14,216 | 4,915 | +189.2% |
| Contract With Customer Liability Noncurrent | 11,776 | — | — |
Show Product Lines breakouts |
|||
| Research and Development Services · Bayer | 1.9 | — | — |
Show Counterparty Name breakouts |
|||
| Alexion License Agreements | 1.6 | — | — |
| Kyowa Kirin Co., Ltd | 8.3 | — | — |
| Other Non-Current Liabilities | 229 | 352 | -34.9% |
| Total Liabilities | 3,639,856 | 2,520,303 | +44.4% |
| Long-Term Debt | 2,652,873 | — | — |
Show Debt Instrument breakouts |
|||
| 2027 Notes, net | 563,750 | — | — |
| 2027 Notes, net · Convertible Debt | 547,483 | — | — |
| 2029 Notes, net | 797,956 | — | — |
| 2029 Notes, net · Convertible Debt | 741,402 | — | — |
| 2031 Notes, net | 625,314 | — | — |
| 2031 Notes, net · Convertible Debt | 565,045 | — | — |
| 2033 Notes, net | 665,853 | — | — |
| 2033 Notes, net · Convertible Debt | 619,631 | — | — |
| Other Liabilities | |||
| Deferred Royalty Obligation Net | 871,185 | 497,299 | +75.2% |
Show Related Party Transactions By Related Party breakouts |
|||
| Related Party | 206,377 | — | — |
Show Type Of Arrangement breakouts |
|||
| Funding Agreement | 561,620 | — | — |
| Royalty Purchase Agreement | 309,565 | — | — |
| Temporary Equity Carrying Amount Net Including Portion Attributable To Noncontrolling Interests | -951 | -227 | -318.9% |
| Stockholders' Equity | |||
| Common Stock | 204 | 197 | +3.6% |
| Treasury Stock Common Value | -405,776 | — | — |
| Additional Paid-In Capital | 2,112,454 | — | — |
| Accumulated Other Comprehensive Income | -8 | — | — |
| Retained Earnings | -3,985,237 | -3,263,685 | -22.1% |
| Total Stockholders' Equity | -2,278,363 | -1,648,395 | -38.2% |
| Minority Interest | 10,439 | 9,957 | +4.8% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -2,267,924 | -1,638,438 | -38.4% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -8 | -3,263,685 | +100.0% |
| Additional Paid In Capital | 2,112,454 | 1,938,369 | +9.0% |
| Common Stock | 204 | 197 | +3.6% |
| Noncontrolling Interest | 10,439 | 9,957 | +4.8% |
| Parent | -2,278,363 | -1,648,395 | -38.2% |
| Retained Earnings | -3,985,237 | -3,263,685 | -22.1% |
| Treasury Stock Common | -405,776 | -323,276 | -25.5% |
| Total Liabilities & Equity | 1,370,981 | 881,638 | +55.5% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Stock-Based Compensation | 33,242 | 25,882 | +28.4% |
| Embedded Derivative Gain Loss On Embedded Derivative Net | -2,158 | -3,952 | +45.4% |
| Amortization Of Financing Costs And Discounts | 1,819 | 1,621 | +12.2% |
Show Debt Instrument breakouts |
|||
| 2027 Notes, net · Convertible Debt | 468 | 455 | +2.9% |
| 2029 Notes, net · Convertible Debt | 513 | 500 | +2.6% |
| 2031 Notes, net · Convertible Debt | 480 | 157 | +205.7% |
| 2033 Notes, net · Convertible Debt | 358 | — | — |
Show Long-Term Debt Type breakouts |
|||
| Convertible Debt | 1,819 | 1,112 | +63.6% |
| Depreciation & Amortization | 1,186 | 1,284 | -7.6% |
| Operating Lease Right Of Use Asset Amortization Expense | 1,466 | 994 | +47.5% |
| Other Non-Cash Items | 306 | -21 | +1557.1% |
| Change in Accounts Receivable | -65,782 | -110,543 | +40.5% |
| Change in Inventory | -7,053 | -3,193 | -120.9% |
| Change in Prepaid & Other Assets | -18,845 | -487 | -3769.6% |
| Increase Decrease In Other Operating Assets | -1,795 | 1,587 | -213.1% |
| Change in Accounts Payable | -7,170 | 17,571 | -140.8% |
| Increase Decrease In Employee Related Liabilities | -37,476 | -19,363 | -93.5% |
| Increase Decrease In Accrued Research And Development Liabilities | 12,994 | -642 | +2124.0% |
| Increase Decrease In Operating Lease Liability | -1,852 | -1,470 | -26.0% |
| Increase Decrease In Deferred Revenue | -2,379 | -2,571 | +7.5% |
| Increase Decrease In Other Operating Liabilities | 4,617 | 2,945 | +56.8% |
Show Related Party Transactions By Related Party breakouts |
|||
| Related Party | 3,622 | — | — |
| Net Cash from Operations | -197,279 | -199,235 | +1.0% |
| Investing Activities | |||
| Purchases of Investments | -52,666 | — | — |
| Proceeds From Sale And Maturity Of Available For Sale Securities | 10,000 | — | — |
| Capital Expenditures | -69 | — | — |
| Net Cash from Investing | -42,735 | -1,595 | -2579.3% |
| Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction | 431 | — | — |
| Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest | -1,955 | -824 | -137.3% |
| Financing Activities | |||
| Proceeds From Convertible Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| 2033 Notes, net | 632,500 | — | — |
| Debt Issuance Costs (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| 2033 Notes, net | -12,796 | — | — |
| Share Repurchases | -82,500 | -48,276 | -70.9% |
| Payment Of Deferred Royalty Obligation | -11,293 | -144 | -7742.4% |
Show Related Party Transactions By Related Party breakouts |
|||
| Related Party | -2,024 | — | — |
| Proceeds From Stock Plans | 5,466 | 3,237 | +68.9% |
| Proceeds From Stock Options Exercised | 22,589 | 2,521 | +796.0% |
| Tax Withholding for Share Compensation | -4,074 | -1,776 | -129.4% |
| Net Cash from Financing | 549,892 | 60,328 | +811.5% |
| Supplemental | |||
| Interest Paid | 20,316 | 23,271 | -12.7% |
| Unpaid Capital Expenditures | 12 | 337 | -96.4% |
| Other Cash Flow | |||
| Net Change in Cash | 309,878 | -140,502 | +320.6% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 882,018 | 542,742 | +62.5% |
| Restricted Cash Current | 550 | 126 | +336.5% |
| Restricted Cash Noncurrent | 1,577 | 2,017 | -21.8% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 882,018 | 542,742 | +62.5% |
Values in thousands USD. Source: SEC EDGAR 10-Q filing.